With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug

By:
On:
URL has been copied successfully!
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.
Please follow us:
Follow by Email
X (Twitter)
Whatsapp
LinkedIn
Copy link

This post was originally published here.